A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
As many as half of obsessive-compulsive disorder (OCD) patients treated with an adequate trial of serotonin reuptake inhibitors (SRIs) fail to fully respond to treatment and continue to exhibit significant symptoms. Many studies have assessed the effectiveness of antipsychotic augmentation in SRI-refractory OCD. In this systematic review, we evaluate the efficacy of antipsychotic augmentation in treatment-refractory OCD. The electronic databases of PubMed, PsychINFO (1967-2005), Embase (1974-2000) and the Cochrane Central Register of Controlled Trials (CENTRAL, as of 2005, Issue 3) were searched for relevant double-blind trials using keywords 'antipsychotic agents' or 'neuroleptics' and 'obsessive-compulsive disorder'. Search results and analysis were limited to double-blind, randomized control trials involving the adult population. The proportion of subjects designated as treatment responders was defined by a greater than 35% reduction in Yale Brown Obsessive-Compulsive Scale (Y-BOCS) rating during the course of augmentation therapy. Nine studies involving 278 participants were included in the analysis. The meta-analysis of these studies demonstrated a significant absolute risk difference (ARD) in favor of antipsychotic augmentation of 0.22 (95% confidence interval (CI): 0.13, 0.31). The subgroup of OCD patients with comorbid tics have a particularly beneficial response to this intervention, ARD=0.43 (95% CI: 0.19, 0.68). There was also evidence suggesting OCD patients should be treated with at least 3 months of maximal-tolerated therapy of an SRI before initiating antipsychotic augmentation owing to the high rate of treatment response to continued SRI monotherapy (25.6%). Antipsychotic augmentation in SRI-refractory OCD is indicated in patients who have been treated for at least 3 months of maximal-tolerated therapy of an SRI. Unfortunately, only one-third of treatment-refractory OCD patients show a meaningful treatment response to antipsychotic augmentation. There is sufficient evidence in the published literature, demonstrating the efficacy of haloperidol and risperidone, and evidence regarding the efficacy of quetiapine and olanzapine is inconclusive. Patients with comorbid tics are likely to have a differential benefit to antipsychotic augmentation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there are some case reports that methylphenidate can worsen OCD symptoms [174] and for some patients antipsychotic medications that reduce dopamine levels are effective [175] (Table 3).”
From Toward a neurocircuit-based taxonomy to guide treatment of obsessive-compulsive disorder (2021) · cites this paper as [175]
In the citing paper
“A meta-analysis of the adult literature examining the use of antipsychotic augmentation in the treatment of OCD showed that the NNT for OCD and tics was 2.3 compared to 5.9 for those with OCD alone.”
From Practice Parameter for the Assessment and Treatment of Children and Adolescents With Tic Disorders (2013) · cites this paper as [139]
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
(1996) · Cited by 6,884
Charbonneau, D. H. (2005) · Europe PMC (PubMed Central) · Cited by 2,041
The Epidemiology of Obsessive-Compulsive Disorder in Five US Communities
Karno, M. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800360042006 · Cited by 1,351
A 40-Year Follow-up of Patients With Obsessive-compulsive Disorder
Skoog, G., & Skoog, I. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.2.121 · Cited by 632
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
McDougle, C. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040046006 · Cited by 570
The International Journal of Neuropsychopharmacology
Lerer, B., Frazer, A., Stahl, S., Farde, L., & Lesch, P. (1998) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145798009018 · Cited by 501
The Epidemiology and Differential Diagnosis of Obsessive-Compulsive Disorder
Rasmussen, S. A., & Eisen, J. L. (1992) · Zwangsstörungen / Obsessive-Compulsive Disorders · doi:10.1007/978-3-642-77608-3_1 · Cited by 493
Treatment non-response in OCD: methodological issues and operational definitions
Pallanti, S., Hollander, E., Bienstock, C., Koran, L., Leckman, J., Marazziti, D., Pato, M., Stein, D., Zohar, J., & International Treatment Refractory OCD Consortium (2002) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145702002900 · Cited by 416
Self-citationCochrane Collaboration Handbook
Mulrow, C. (1996) · Medical Entomology and Zoology · Cited by 403
Efficacy of Fluvoxamine in Obsessive-Compulsive Disorder: A Double-blind Comparison With Placebo
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810010038006 · Cited by 390
Clomipramine in the Treatment of Patients With Obsessive-Compulsive Disorder
(1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810320054008 · Cited by 388
Quality of life for patients with obsessive-compulsive disorder
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.6.783 · Cited by 367
A placebo-controlled trial of risperidone in Tourette syndrome
Scahill, L., Leckman, J. F., Schultz, R. T., Katsovich, L., & Peterson, B. S. (2003) · Neurology · doi:10.1212/01.wnl.0000055434.39968.67 · Cited by 362
Self-citationShapiro, E. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810080052006 · Cited by 355
BindingDB (2011) · PubMed · doi:10.7270/q2cr5rw8 · Cited by 333
Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder
(1990) · American Journal of Psychiatry · doi:10.1176/ajp.147.5.652 · Cited by 271
Obsessional Neurotics: A Long-term Follow-up
Kringlen, E. (1965) · British Journal of Psychiatry · doi:10.1192/bjp.111.477.709 · Cited by 259
Denys, D., de Geus, F., van Megen, H. J. G. M., & Westenberg, H. G. M. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0803 · Cited by 248
Epidemiology of obsessive-compulsive disorder: a world view.
Sasson, Y., Zohar, J., Chopra, M., Lustig, M., Iancu, I., & Hendler, T. (1997) · PubMed · Cited by 244
Clinical Predictors of Drug Response in Obsessive-Compulsive Disorder
Erzegovesi, S., Cavallini, M. C., Cavedini, P., Diaferia, G., Locatelli, M., & Bellodi, L. (2001) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200110000-00006 · Cited by 224
Bystritsky, A., Ackerman, D. L., Rosen, R. M., Vapnik, T., Gorbis, E., Maidment, K. M., & Saxena, S. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0418 · Cited by 220
Follow-Up Studies in Obsessional Neurosis
Goodwin, D. W. (1969) · Archives of General Psychiatry · doi:10.1001/archpsyc.1969.01740140054006 · Cited by 214
Hollander, E., Rossi, N. B., Sood, E., & Pallanti, S. (2003) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145703003730 · Cited by 197
Development of a quality assessment instrument for trials of treatments for depression and neurosis
Moncrieff, J., Churchill, R., Drummond, D. C., & McGuire, H. (2001) · International Journal of Methods in Psychiatric Research · doi:10.1002/mpr.108 · Cited by 185
Predictors of drug treatment response in obsessive-compulsive disorder.
Ravizza, L., Barzega, G., Bellino, S., Bogetto, F., & Maina, G. (1995) · PubMed · Cited by 182
Stein, D. J., Bouwer, C., Hawkridge, S., & Emsley, R. A. (1997) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v58n0306 · Cited by 169
McDougle, C. J., Price, L. H., Goodman, W. K., Charney, D. S., & Heninger, G. R. (1991) · PubMed · Cited by 161
Risperidone in the treatment of affective illness and obsessive-compulsive disorder.
Fm, J. (1995) · PubMed · Cited by 158
Shapira, N. A., Ward, H. E., MANDOKI, M. W., Murphy, T. K., Yang, M. C. K., Blier, P., & Goodman, W. K. (2004) · Biological Psychiatry · doi:10.1016/j.biopsych.2003.11.010 · Cited by 154
Erzegovesi, S., Guglielmo, E., Siliprandi, F., & Bellodi, L. (2004) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2004.04.004 · Cited by 138
Ein Beitrag zur Frage der Zwangskrankheit, insbesondere ihrer heredit�ren Beziehungen
Zerbin-Rüdin, E. (1953) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf00345572 · Cited by 135
McDOUGLE, C. J., PRICE, L. H., GOODMAN, W. K., CHARNEY, D. S., & HENINGER, G. R. (1991) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199106000-00005 · Cited by 134
Carey, P. D., Vythilingum, B., Seedat, S., Muller, J. E., van Ameringen, M., & Stein, D. J. (2005) · BMC Psychiatry · doi:10.1186/1471-244x-5-5 · Cited by 133
Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: three cases.
McDougle, C. J., Fleischmann, R. L., Epperson, C. N., Wasylink, S., Leckman, J. F., & Price, L. H. (1995) · PubMed · Cited by 130
Self-citationCORYELL, W. (1981) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-198104000-00003 · Cited by 117
PIGOTT, T. A., LʼHEUREUX, F., HILL, J. L., BIHARI, K., BERNSTEIN, S. E., & MURPHY, D. L. (1992) · Current Opinion in Cardiology · doi:10.1097/00001573-199202000-00003 · Cited by 113
Uncomplicated and comorbid obsessive-compulsive disorder in an epidemiologic sample
Hollander, E., Greenwald, S., Neville, D., Johnson, J., Hornig, C. D., & Weissman, M. M. (1996) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1996)4:3<111::aid-da3>3.0.co;2-j · Cited by 112
Li, X., May, R. S., Tolbert, L. C., Jackson, W. T., Flournoy, J. M., & Baxter, L. R. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0610 · Cited by 110
Fineberg, N. A., Sivakumaran, T., Roberts, A., & Gale, T. (2005) · International Clinical Psychopharmacology · doi:10.1097/00004850-200507000-00005 · Cited by 105
Biological Approaches to Treatment-Resistant Obsessive-Compulsive Disorder
(2017) · Obsessive-Compulsive Disorder · doi:10.4324/9781315561073-31 · Cited by 97
Obsessive-compulsive disorder: diagnosis and treatment.
Goodman, W. K. (1999) · PubMed · Cited by 93
A Predictive Study of Obsessive-Compulsive Disorder Response to Clomipramine
ALARCON, R. D., LIBB, J. W., & SPITLER, D. (1993) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199306000-00010 · Cited by 91
Kiene, H., Kienle, G. S., & von Schoen-Angerer, T. (2006) · Homeopathy · doi:10.1016/j.homp.2005.11.006 · Cited by 79
Pharmacological Management of Obsessive-Compulsive Disorder: A Review for Clinicians
McDonough, M., & Kennedy, N. (2002) · Harvard Review of Psychiatry · doi:10.1080/10673220216215 · Cited by 44
Ein Beitrang zur Frage der Zwangskrankheit, in sobesondere ihrere hereditaren Beziehungen
Rudin, E. (1953) · Medical Entomology and Zoology · Cited by 17
LANGSTRECKEN‐KATAMNSESEN VON ZWANGSNEUROSEN1
Delkeskamp, H. (1965) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1965.tb06170.x · Cited by 13
Obsessive-Compulsive Disorders in Cambridgeshire
Berrios, G. E., & Chiu, H. F. K. (1989) · The British Journal of Psychiatry · doi:10.1192/s0007125000295706 · Cited by 8
Research works printed but not linked: 2
- Muller C . Vorlaufige Mitteilung zur langen Katamnese der Zwangskranken. Nervenartz 1953; 24: 112–115.
- Rennie TAC . Prognosis in the Psychoneurosis: Benign and Malignant Developments, Current Problems in Psychiatric Diagnosis. New York: Grune & Stratton Inc, 1953.
Cited by
Psychiatric Comorbidities and Schizophrenia
Buckley, P. F., Miller, B. J., Lehrer, D. S., & Castle, D. J. (2009) · Schizophrenia Bulletin · doi:10.1093/schbul/sbn135 · Cited by 1,121
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“response rates [816,817].”
Neurocognitive endophenotypes of impulsivity and compulsivity: Towards dimensional psychiatry
Robbins, T. W., Gillan, C. M., Smith, D. G., de Wit, S., & Ersche, K. D. (2012) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2011.11.009 · Cited by 1,003
Abramowitz, J. S., Taylor, S., & McKay, D. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60240-3 · Cited by 1,002
Stein, D. J., Costa, D. L. C., Lochner, C., Miguel, E. C., Reddy, Y. C. J., Shavitt, R. G., van den Heuvel, O. A., & Simpson, H. B. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0102-3 · Cited by 895
Metadata
- Authors
- Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F.
- Affiliations
- Yale University (US)
- Connecticut Mental Health Center (US)
- Corresponding author
- Bloch, M H
- Venue
- Molecular Psychiatry
- Published
- 2006-04-04
- Volume
- 11
- Issue
- 7
- Pages
- 622-632
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2100202859
- Cited by
- 635
- References
- 50
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 22 · 2023: 14 · 2022: 18 · 2021: 25 · 2020: 21 · 2019: 29 · 2018: 34 · 2017: 37 · 2016: 30 · 2015: 53 · 2014: 48 · 2013: 39 · 2012: 39
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Update notices
- erratum (2006-07-26)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Tourette Association of America
- National Institutes of Health
- U.S. Public Health Service
- National Institute of Mental Health
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- obsessive-compulsive disorder, treatment-refractory OCD, antipsychotic augmentation, serotonin reuptake inhibitors, haloperidol, risperidone, quetiapine, olanzapine, treatment response, Yale-Brown Obsessive Compulsive Scale
- MeSH terms
- Quetiapine Fumarate, Olanzapine, Adult, Aged, Basal Ganglia Diseases, Benzodiazepines, Depressive Disorder, Dibenzothiazepines, Double-Blind Method, Drug Resistance, Drug Therapy, Combination, Haloperidol, Humans, Middle Aged, Obsessive-Compulsive Disorder, Patient Dropouts, Tic Disorders, Antipsychotic Agents, Comorbidity, Randomized Controlled Trials as Topic, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.